HIGHFDA DRUG

Exela Pharma Sciences 4.2% Sodium Bicarbonate Injection Recalled Over Arsenic Impurity Out-Of-Spec

Exela Pharma Sciences recalls 4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10 mL, nationwide in the U.S. The recall cites out-of-spec arsenic impurities. Consumers should stop use and contact a healthcare provider. Follow recall notice for guidance and refunds.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
July 30, 2025
Status
ACTIVE
Severity
9/10

Quick Facts at a Glance

Recall Date
July 30, 2025
Hazard Level
HIGH
Brands
SODIUM BICARBONATE, Exela Pharma Sciences
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT, PETS

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
SODIUM BICARBONATE, Exela Pharma Sciences
Product type
Intravenous Sodium Bicarbonate Injection
Model numbers
Lot # 10004077, Exp. 02/28/2026
UPC codes
51754-5001, 51754-5011, 51754-5002, 51754-5012, 51754-5001-5, 51754-5001-4, 51754-5011-4, 51754-5002-5 +2 more
Sizes
10 mL single-dose vial
Sold at
Unknown
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    July 30, 2025

  2. Reported by FDA DRUG

    September 17, 2025

  3. RecallRadar source check

    April 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Failed Impurities/Degradation Specifications: out of specification results for arsenic in the impurities tested.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Exela Pharma Sciences LLC or your healthcare provider for guidance. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

About This Product

IV sodium bicarbonate injection used to treat acid-base disorders and metabolic acidosis in hospitalized patients.

Why This Is Dangerous

Arsenic impurities in impurities tested may pose serious safety risks if administered intravenously.

Industry Context

This recall is not clearly described as part of a broader industry pattern.

Real-World Impact

Immediate discontinuation advised. Potential safety risk to patients receiving IV treatment.

Practical Guidance

How to identify if yours is affected

  1. Confirm Lot # 10004077 and Expiration 02/28/2026.
  2. Verify packaging shows Exela Pharma Sciences, Lenoir, NC.

Where to find product info

FDA enforcement report linked in recall notice for full scope.

What timeline to expect

Consumers should expect recall communications and guidance to be issued within days; replacement or refund processes follow company notification.

If the manufacturer is unresponsive

  • Contact FDA for guidance.
  • File a consumer safety complaint if the company is unresponsive.

How to prevent similar issues

  • Always verify NDCs before administration.
  • Ensure hospital inventory management flags recalled lots.
  • Coordinate with suppliers for recalls and replacements.

Documentation advice

Keep copy of recall notification, NDCs, lot number, expiration date, and correspondence with manufacturer.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Product: 4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10 mL (0.5 mEq/mL). Form: 10 mL single-dose vial. Type: Intravenous use only. Rx only. Manufactured and distributed by Exela Pharma Sciences, LLC, Lenoir, NC 28645 USA. NDC: 51754-5012-1 (vial); 51754-5012-4 (carton). Sold nationwide in the USA. Lot: 10004077. Expiration: 02/28/2026.

Reported Incidents

No specific patient injury or incident counts are provided in the notice. The status remains ACTIVE and classified as HIGH hazard.

Key Facts

  • HIGH hazard level
  • Arsenic impurity out-of-specification
  • Nationwide distribution in USA

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
9/ 10
Affected Groups
GENERALPREGNANTPETS
Injury Types
POISONINGELECTRICAL

Product Details

Model Numbers
Lot # 10004077
Exp. 02/28/2026
UPC Codes
51754-5001
51754-5011
51754-5002
+7 more
Affected States
ALL
Report Date
September 17, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

SUN PHARMACEUTICAL INDUSTRIES
Labeling: Not
Read more